IMUGENE LIMITED — Director's Dealing 2021

Jul 4, 2021

==> picture [116 x 41] intentionally omitted <==

ASX Announcement 05 July 2021

Dr Lesley Russell (Non-Executive Director) increases shareholding following exercise of options

---

I am delighted to advise that Imugene's Non-Executive Director, Dr Lesley Russell, has elected to exercise her options to increase her shareholding in the Company to 13.7 million shares.

Please find attached the Appendix 3Y following the change of holding by Dr Russell, which contains further details.

Paul Hopper

Executive Chairman

-End-

info@imugene.com

IMUGENE LIMITED ACN 009 179 551

WWW.IMUGENE.COM

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

ntroduced 30/9/2001. Ame	nded 01/01/11
	Imugene Limited (ASX:IMU)
Name of Entity:
	009 179 551
ACN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr Lesley Russell
Date of Last Notice:	30 March 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevantinterest.
Date of change		29 June 2021 to 1 July 2021
No. of securities held prior to change				Options 25,000,000 - 25,000,000
			Shares	Options
		Direct	500,000	25,000,000
		Indirect	-	-
		Total	500,000	25,000,000
Class		Fully Paid Ordinary Shares Unlisted Options		(IMU) and
Number acquired				Options - - -
			Shares	Options
		Direct	a) 15,000,000	-
		Indirect	-	-
		Total	15,000,000	-
Number disposed				Options a) 15,000,000 - 15,000,000
			Shares	Options
		Direct	b) 1,800,000	a) 15,000,000
		Indirect	-	-
		Total	1,800,000	15,000,000

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		a) between $0.040 and $0.042 per share b) $629,080	a) between $0.040 and $0.042 per share b) $629,080	a) between $0.040 and $0.042 per share b) $629,080
No. of securities held after change				Options 10,000,000 - 10,000,000
			Shares	Options
		Direct	13,700,000	10,000,000
		Indirect	-	-
		Total	13,700,000	10,000,000
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back		a) Exercise of Options. b) On-Market Trade.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

==> picture [39 x 24] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011